Haematologica (Aug 2007)

The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)

  • Faith E. Davies,
  • Ping Wu,
  • Matthew Jenner,
  • Muralikrishan Srikanth,
  • Radovan Saso,
  • Gareth J. Morgan

DOI
https://doi.org/10.3324/haematol.11228
Journal volume & issue
Vol. 92, no. 8

Abstract

Read online

The combination of bortezomib (velcade), pulsed dexamethasone and weekly cyclophosphamide (CVD) in relapsed/refractory myeloma patients induces high overall (75%) and complete (31%) response rates compared to velcade/dexamethasone (overall 47%, CR 5%) and velcade alone (overall 27%, CR 0%). The toxicity profiles including thrombocytopenia, neutropenia, and neuropathy were comparable between the groups.